3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
6
Genitourinary
5
Other hematologic neoplasm
4
Lymphoid
4
Dermatologic
4
CNS
4
Thoracic
3
Gastrointestinal
3
Sarcoma
2
Gynecologic
2
Plasma cell
1
Breast
1
Conditions
Breast Neoplasms
40
Triple Negative Breast Neoplasms
34
Carcinoma, Non-Small-Cell Lung
28
Melanoma
18
Ovarian Neoplasms
16
Carcinoma, Renal Cell
16
Neoplasm Metastasis
13
Pancreatic Neoplasms
12
Carcinoma, Transitional Cell
12
Colorectal Neoplasms
11
Stomach Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
9
Neoplasms
9
Uterine Cervical Neoplasms
7
Lung Neoplasms
7
Head and Neck Neoplasms
7
Endometrial Neoplasms
7
Carcinoma, Merkel Cell
7
Carcinoma, Hepatocellular
7
Small Cell Lung Carcinoma
6
Prostatic Neoplasms
6
Gastrointestinal Neoplasms
5
Sarcoma
4
Mesothelioma
4
Urinary Bladder Neoplasms
3
Lymphoma
3
Hodgkin Disease
3
Esophageal Neoplasms
3
Cholangiocarcinoma
3
Carcinoma, Ovarian Epithelial
3
Interventions
Cyclophosphamide
6
Radiotherapy
5
olaparib
3
exemestane
3
Paclitaxel
3
Letrozole
3
Itraconazole
3
Gemcitabine
3
Fulvestrant
3
Carboplatin
3
Blood Specimen Collection
3
palbociclib
2
fludarabine phosphate
2
eribulin
2
avelumab
2
abemaciclib
2
Therapeutics
2
Polymerase Chain Reaction
2
Peripheral Blood Stem Cell Transplantation
2
Melphalan
2
Mastectomy
2
Flow Cytometry
2
Filgrastim
2
Exercise
2
Everolimus
2
Etoposide
2
Dasatinib
2
Cetuximab
2
Carmustine
2
Bevacizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Nivolumab
×
Breast
×
Clear all
NCT03435640
2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2
Terminated
64 enrolled
22 charts